Patients displaying CAPS-associated symptoms have been shown to carry a set of NLRP12 but not always NLRP3 mutations, considered to dysregulate NLRP12 inflammasome activation and trigger the NLRP12-associated auto-inflammatory diseases (NLRP12-AID) [307–309]. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.